Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation
| العنوان: | Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation |
|---|---|
| المؤلفون: | Antoine Hadengue, Hanspeter Egger, Emiliano Giostra, Gilles Mentha, Ronald Fried, Francesco Negro, Pierre-Alain Clavien, Stephan Kraehenbuhl, Gerd A. Kullak-Ublick, Walter Keller, Claire Vanlemmens, Philippe Morel, Sandrine Locher |
| المصدر: | Transplant International, Vol. 17, No 4 (2004) pp. 169-76 |
| سنة النشر: | 2003 |
| مصطلحات موضوعية: | Male, Cirrhosis, Time Factors, medicine.medical_treatment, Hepacivirus, Liver transplantation, ddc:616.07, Liver Transplantation/adverse effects, medicine.disease_cause, Gastroenterology, Severity of Illness Index, chemistry.chemical_compound, Recurrence, Medicine, ddc:616, biology, ddc:617, Hepatitis C, Middle Aged, Viral Load, Treatment Outcome, RNA, Viral, Drug Therapy, Combination, Female, Viral load, Antiviral Agents/administration & dosage, Adult, medicine.medical_specialty, Hepacivirus/genetics/isolation & purification, Hepatitis C/drug therapy/pathology, Hepatitis C, Chronic/prevention & control, Hepatitis C virus, Interferon-alpha/administration & dosage, Antiviral Agents, Drug Administration Schedule, Internal medicine, Ribavirin, Humans, RNA, Viral/blood, Aged, Transplantation, business.industry, Interferon-alpha, Hepatitis C, Chronic, medicine.disease, biology.organism_classification, Liver Transplantation, chemistry, Immunology, business, Ribavirin/administration & dosage |
| الوصف: | Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), and sequels of chronic hepatitis of the graft are a significant cause of morbidity and mortality. In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg body weight q.d.) for 12 weeks, followed by ribavirin at the same dose q.d. plus interferon-alpha (IFN-alpha) [3 million units three times a week (3 MU TIW)] for another 48 weeks. Based on an intent-to-treat analysis, the percentages of patients with undetectable HCV RNA in their serum were 0%, 38.7% and 45.2% after 12, 36 and 60 weeks of therapy, respectively. A sustained virological response, as defined by undetectable serum HCV RNA 24 weeks after the end of treatment, was observed in 9/31 patients (29%). Sustained responders had a significant improvement of their liver inflammatory activity score (P=0.025), but not of their liver fibrosis score. The chances of sustained virological response correlated with the length of treatment, but not with the HCV genotype or baseline HCV RNA level. In conclusion, patients with recurrent hepatitis C after LT might benefit from ribavirin/IFN-alpha therapy, provided that the treatment is tolerated for a sufficient duration of time. |
| تدمد: | 0934-0874 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::823ff6b5b459a51378d60f3a6cdf2eec https://pubmed.ncbi.nlm.nih.gov/15060764 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....823ff6b5b459a51378d60f3a6cdf2eec |
| قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!